Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06910124 · ClinicalTrials.gov registry record · Phase 2

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

A Phase 2 study of Multiple Myeloma, sponsored by Dickran Kazandjian, MD.

Recruiting
Registry status
Phase 2
Development phase
32
Enrollment target
1
Study location

NCT06910124 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Dickran Kazandjian, MD. The registered enrollment target is 32 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06910124, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Dickran Kazandjian, MD.

RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1. Get rid of any residual multiple myeloma cells in participants' bodies which is known as minimal residual disease negative (MRD-) status. For participants that start the study with residual multiple myeloma cells in participants' bodies: to determine how long you remain MRD-. 2. Increase the length of time that participants' disease is controlled. For participants with relapsed disease, to determine whether participants can re-attain MRD- status. 3. Increase the length of time that participants' disease responds to treatment. The researchers also want to find out the effects that linvoseltamab has on participants and participants' condition.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Lenalidomide
  • BIOLOGICAL Linvoseltamab

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-12-02
Est. Completion 2032-12-02
Phase Phase 2

Sponsor

Dickran Kazandjian, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06910124

The ClinicalTrials.gov registry entry for NCT06910124 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The listed sponsor is Dickran Kazandjian, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.

NCT06910124 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06910124 about?

NCT06910124 is a clinical study titled "Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse". The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1. Get rid of any residual multiple myeloma cells in participants' bodies which is known as minimal residual disease negative (MRD-) stat...

What is the current status of trial NCT06910124?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-12-02. Estimated completion is 2032-12-02.

What conditions does trial NCT06910124 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06910124?

The interventions under investigation include: Lenalidomide (DRUG), Linvoseltamab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06910124?

This trial is sponsored by Dickran Kazandjian, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06910124 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.